Type 1 Diabetes

CKD risk not necessarily tied to albuminuria in patients with type 1 diabetes.

Management of non-glycemic cardiovascular disease risk factors may have increasing benefits in an aging type 1 diabetes patient population with long-term hyperglycemia.

Serum concentration levels of both chromium and manganese metals are altered in people with and without diabetes.

Study focuses on quality and quantity of carb consumption during pregnancy.

Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.

People with type 1 diabetes receiving once-daily injection of glucagon-blocking drug, REMD-477 can reduce their insulin use considerably and improve blood glucose levels without altering hypoglycemia.

In adults with two or more antibodies predicting the development of type 1 diabetes, treatment with daily oral insulin therapy did not prevent development of the disease, but a small subset experienced a 31-month delay in clinical diabetes development.

Research will still continue due to its safety.

Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.

Results from two studies demonstrate improved glycemic control, reduction in nighttime- and exercise-induced hypoglycemia with the use of hybrid closed-loop systems.